Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

BOULDER, Colo. and MONTREAL, Jan. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the enrollment of the first patient in a Phase 2 clinical trial (Trial CL002) evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Vidaza(R) (azacitidine for injection), Pharmion's DNA demethylating agent, in patients with relapsed or refractory Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL).

Patients will receive 75 mg/m2 of Vidaza either intravenously or subcutaneously in combination with an oral dose of MGCD0103 in 28 day cycles. Key objectives for this study are to determine the overall response rate, progression free survival and duration of response. The trial will enroll up to 75 patients at cancer centers in North America and will include a pharmacokinetic equivalency study.

"We are aggressively exploring the utility of epigenetic drug combinations in the treatment of cancer," said Andrew Allen, Pharmion's executive vice president and chief medical officer. "The biology of cancer suggests multiple epigenetic mechanisms cooperate to silence tumor suppressor genes, which raises the simple hypothesis that attacking these mechanisms with drug combinations may be superior to single-agent therapy. In this trial, we are combining Vidaza, our DNA methyltransferase inhibitor, with MGCD0103, our isotype-selective HDAC inhibitor, in a clinical study of this therapeutic approach. We are unique in our ability to conduct a trial like this, using drugs from our own portfolio."

"We are delighted to be participating in this trial of Vidaza and MGCD0103," commented Dr. Anas Younes, Professor of Medicine
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015   Decision Resources Group ... in dialysis patient management in the U.S. versus ... by U.S. and EU5 nephrologists from approximately 1,870 ... are the most commonly used renal medications in ... differs considerably between the two regions.      ...
(Date:7/7/2015)... FRANCISCO , July 7, 2015 ... reach USD 1,197.7 million by 2020, growing at an estimated ... new study by Grand View Research, Inc. Introduction of innovative ... coupled with growing awareness levels pertaining to the advantages of ... the next six years. In addition, presence of untapped growth ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... CHICAGO and ORANGE, Calif., Feb. 23, 2011 ... (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in ... in California, West Texas and Eastern New Mexico, has selected ... MDRX ) to streamline patient movement through their ...
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Silverado today ... break ground as early as Summer 2015 on a four-acre site in Bellingham, Washington. ... with the support of city officials and other members of the local community. , ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... Southwest, including Giant, Mustang, Sun Dial and Howdy’s, raised more than $524,286 ... 2015 fundraising goal by nearly $100,000, to help support children fighting muscular ...
(Date:7/7/2015)... Angeles, CA (PRWEB) , ... July 07, 2015 ... ... International Business Times highlights rumors about possible facial rejuvenation that have emerged about ... year-old former U.S. Secretary of State looks more youthful than she has in ...
(Date:7/7/2015)... ... 07, 2015 , ... Quadrino Law Group is pleased to announce the relocation ... 11747. The new facility is a state of the art building, located with ... the firm's CEO and founder, said, "We are pleased to service our clients from ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Safe Catch ... every single fish for mercury. Albertsons, Gelson’s Markets, New Leaf Community Markets, Sprouts Farmers ... tuna. , “We developed the technology to test every fish for mercury,” said Safe ...
Breaking Medicine News(10 mins):Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2
... Take "Wait and See" Approach to Identifying,Learning Disabilities, ... Learning,a nonprofit program of the Charles and Helen ... learning and attention problems,announced today their launch of ... child may have a learning problem. This one-of-a-kind,resource, ...
... Platform Delivers Real Time, Comprehensive and Seamless Public, ... Information, PHILADELPHIA, Sept. 10 Thomson Scientific,part ... TSX: TOC) and leading provider,of information solutions to ... release of BONDplus, an integrated,web-based data platform to ...
... Coalition America, Inc. (CAI),announces the addition of ... lead the deployment efforts of CAI,s new key ... development,initiatives. Brown comes to CAI with over ... held management roles in various locations,throughout the country ...
... post-operative pain control methods have proved inadequate for ... according to University of Iowa College of Nursing ... nursing, was recently awarded a $2.1 million grant ... study the use of balanced nonpharmacologic and pharmacologic ...
... to Promote Healthy ... Eating and Physical Activity, DIGHTON, Kan. and WILMINGTON, ... teach children ages,6-12 healthy habits both at home and at school. ... will provide,250 schools, as well as students, families, with resources and ...
... feel better, researchers say , MONDAY, Sept. 10 (HealthDay ... or terminal cancer suffer from depression, anxiety or adjustment ... according to a new study. , Physicians treating the ... most valuable screening tool is simply listening, the researchers ...
Cached Medicine News:Health News:Schwablearning.Org Launches Interactive Tool to Help Parents of Children Struggling in School 2Health News:Thomson Scientific Announces BONDplus for Biological Researchers 2Health News:Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer 2Health News:Back-to-School Campaign Motivates Children and Parents to Embrace 'Habits for Health' 2Health News:Back-to-School Campaign Motivates Children and Parents to Embrace 'Habits for Health' 3Health News:Back-to-School Campaign Motivates Children and Parents to Embrace 'Habits for Health' 4Health News:Mental Health Woes Strike Half of Cancer Patients 2
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: